The purpose of this study is to find the highest dose of an investigational drug called AGS-16C3F that can be given safely in patients with renal cell cancer that has spread despite prior therapy. Patients with the clear cell type of renal cell carcinoma are most likely to benefit from this drug; patients with non-clear cell cancers will have their tumors tested to see if they might respond to AGS-16C3F.
AGS-16C3F is an antibody-drug conjugate. It is composed of an antibody which binds to a specific receptor on cancer cells. Once there, a chemotherapy drug that is bound to the antibody can kill the cancer cell. AGS-16C3F is given intravenously (by vein).